A groundbreaking study published in the prestigious journal Cell has uncovered a startling gap in the gut microbiomes of infants across the UK and much of Europe: the near-total absence of a key probiotic bacterium known as Bifidobacterium infantis (B. infantis). This 'missing microbe,' which plays a crucial role in digesting breast milk components and protecting against pathogens, is commonplace in babies from Africa and South Asia but virtually absent in Western infants. Researchers warn that this discrepancy could have profound implications for early-life health, prompting calls for a rethink in infant probiotic formulations and microbiome interventions tailored to regional differences.
The discovery stems from the largest-ever global atlas of infant gut bacteria, cataloging over 4,000 genomes from 48 countries. Led by teams from the Wellcome Sanger Institute, KEMRI-Wellcome Trust Research Programme, and the UK Baby Biome study, the research reveals how modern lifestyles—ranging from C-section births and formula feeding to antibiotic use—may be disrupting the natural seeding of beneficial bacteria at birth. As pioneer colonizers, these microbes shape the entire trajectory of gut development, immune training, and nutrient absorption during the critical first months of life.
🔬 The Science Behind the Global Microbiome Atlas
The study, titled "Genomic atlas of Bifidobacterium infantis and B. longum informs infant probiotic design," analyzed metagenomic data from thousands of stool samples worldwide. Key cohorts included the UK Baby Biome study—a longitudinal birth cohort tracking over 1,100 healthy UK newborns—and the CHAIN Network, which sampled 3,101 acutely ill children under two from Bangladesh, Burkina Faso, Kenya, Malawi, Pakistan, and Uganda.
Using advanced sequencing techniques like Illumina NovaSeq and Oxford Nanopore, researchers assembled 4,098 high-quality genomes, boosting representation from sub-Saharan Africa and South Asia by 17-fold. This revealed B. infantis prevalence at around 80% in low- and middle-income country (LMIC) infants under six months, dropping to just 1.6% in high-income country (HIC) infants under two months—and even rarer in UK samples.
Phylogenomic analysis confirmed B. infantis and B. longum as distinct species, with the former showing extreme biogeographic stratification into 36 region-specific strains. These strains carry unique genes adapted to local diets, such as those for breaking down fonio millet in West Africa or diverse human milk oligosaccharides (HMOs) globally.
What Makes B. infantis Essential for Infant Health?
Bifidobacterium infantis is one of the first bacteria to colonize the newborn gut, often arriving via vaginal birth and thriving on HMOs—complex sugars in breast milk that humans can't digest but which fuel beneficial microbes. Step-by-step, it ferments HMOs into short-chain fatty acids, strengthening the gut barrier, modulating immune responses, and crowding out pathogens like Clostridium difficile.
- Nutrient absorption: Enhances uptake of vitamins and minerals from breast milk.
- Immune training: Promotes regulatory T-cells, reducing allergy and infection risks.
- Microbiome stability: Prevents dysbiosis linked to colic, eczema, and later metabolic disorders.
In its absence, European infants rely more on B. longum subsp. longum, which is less specialized for HMOs and associated with different metabolic profiles. While not immediately harmful, this shift may contribute to rising rates of childhood allergies (up 50% in UK over 20 years) and gastrointestinal issues.
Why Is B. infantis Vanishing from European Babies?
Several interconnected factors explain the decline:
- Delivery mode: C-sections (30% in UK vs. lower in LMICs) bypass maternal vaginal microbes.
- Feeding practices: Formula use disrupts HMO supply; exclusive breastfeeding rates drop after three months.
- Antibiotics: Early prescriptions wipe out pioneer bacteria; UK infants average 2-3 courses by age two.
- Hygiene and urbanization: Reduced exposure to diverse microbes; sanitized environments limit natural colonization.
- Weaning diets: Processed foods favor different bacteria over HMO specialists.
Historical data shows B. infantis was more common pre-1950s, suggesting industrialization accelerated its loss. In contrast, LMIC infants benefit from prolonged breastfeeding (average 18 months) and plant-rich diets fostering strain diversity.
A 2022 Stanford study echoed this, noting U.S. infants missing B. infantis due to formula dominance, linking it to inflammation risks.
Global Comparisons: Europe Lags Behind LMICs
The atlas paints a stark picture:
| Region | B. infantis Prevalence (<6 months) | Dominant Alternative |
|---|---|---|
| UK/Europe/North America | 1-5% | B. longum subsp. longum |
| Sub-Saharan Africa | 80-95% | B. infantis (dominant) |
| South Asia | 75-90% | B. infantis (dominant) |
This disparity highlights how Western microbiomes are 'depauperate,' potentially heightening vulnerability to infections. CHAIN data showed B. infantis inversely correlated with severe illness in LMIC children.
Figure from the study illustrating regional dominance.
Health Risks: From Short-Term Issues to Lifelong Impacts
While direct causation isn't established, absence of B. infantis correlates with:
- Increased colic and reflux (20-30% higher in Western cohorts).
- Elevated allergy risk (eczema up 40% in B. infantis-low infants).
- Gut permeability issues, potentially seeding obesity, asthma, IBD later.
- Neurodevelopmental links: HMOs support brain glycans; dysbiosis tied to ADHD/autism risks.
UK data from Baby Biome links early dysbiosis to hospitalization rates. Long-term, Western microbiome shifts mirror rising NCDs (non-communicable diseases), per WHO reports.
WHO NCD factsheetProbiotics Under Scrutiny: Outdated Strains Fail Modern Infants
Commercial products like those with B. infantis EVC001 trace to 1950s U.S. isolates—clonal and mismatched to current strains. Engraftment fails in 70-90% of cases outside HICs, per trials. FDA warnings highlight sepsis risks in preterms.
The atlas proposes solutions: Use geo-specific strains (e.g., African-adapted for Europe trials) paired with prebiotics. Ongoing REMEDI4MIC trials test this; early data shows 80% engraftment boost.
Study figure on strain diversity.
Explore microbiome research positions in Europe to advance this field.The UK Baby Biome Study: A European Pioneer
Funded by Wellcome (£20m+), this cohort tracks 6,000+ families, linking microbiomes to health outcomes via EHRs. Findings: UK C-section babies 50% less likely to acquire B. infantis; formula-fed even lower. Expansions to Europe (e.g., Sweden cohorts) confirm pattern.
Stakeholders like NHS urge screening; pediatricians recommend breastfeeding + synbiotics.
Expert Perspectives: Calls for Urgent Action
"Lifestyle changes are reshaping infant microbiomes from birth," says Dr. Trevor Lawley (Sanger). Prof. Jay Berkley (CHAIN) stresses LMIC data gaps: "17-fold boost reveals tailored needs." Dr. Yan Shao advocates: "Next-gen probiotics using evolved strains."
European experts echo: Italian/Spanish cohorts show similar absences, linking to Mediterranean diet shifts.
Solutions and Future Outlook for Europe
Short-term:
- Promote vaginal births, skin-to-skin, exclusive breastfeeding 6 months.
- Trial geo-adapted probiotics (e.g., EU-funded pilots).
Long-term: Policy for antibiotic stewardship, HMO-fortified formulas. Horizon Europe funds £100m+ microbiome projects; watch 2027 trials.
Optimism: Atlas is open-access; startups like Probiota Europe developing strains. Parents: Consult pediatric microbiologists via academic networks.
Photo by Elle Cartier on Unsplash
Actionable Insights for European Parents and Clinicians
- Monitor symptoms like persistent colic; test microbiome if recurrent infections. - Choose probiotics with live cultures matching strains (e.g., Evivo for B. infantis, under doc advice). - Advocate vaginal microbiome transplants (experimental). For researchers: Jobs in infant microbiome abound at Sanger, Oxford.
Europe's infants deserve microbiomes as robust as their global peers—tailored science paves the way.